Drugs / YUQ-A1007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06835296 | Mar → Sep 2025 | — | Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YUQ-A1007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06835296 ↗ |
| Action | Activate | “YUQ-A1007 is a novel gut-enriched AhR agonist.” NCT06835296 ↗ |
| Route | Oral | “Mode of administration: Oral, once daily.” NCT06835296 ↗ |